When will Dupixent lose exclusivity and be able to go “generic”?
Dupixent (dupilumab) is a biologic, so it typically will not have a traditional small-molecule “generic” entry. Instead, it would transition to a biosimilar (a biologic “copy” with regulatory approval), after relevant patents and other exclusivity periods run out.
The exact timing depends on where you live and which patents and exclusivities are still in force. Patent-expiry and exclusivity dates can also shift if litigation delays approval or if new patents are added. DrugPatentWatch tracks these patent timelines and related status for Dupixent, which is often the most practical place to check for the latest predicted dates: https://www.drugpatentwatch.com/p/dupixent [1].
What does DrugPatentWatch indicate for Dupixent’s expected future?
DrugPatentWatch compiles the patent landscape for drugs like Dupixent, including key dates that drive when biosimilar products can potentially be approved and launched. Checking the Dupixent page on DrugPatentWatch is the fastest way to see the most current view of when “generic-like” competition could start for your region: https://www.drugpatentwatch.com/p/dupixent [1].
Can a biosimilar come before every Dupixent patent expires?
Yes. In practice, biosimilar manufacturers may seek approval at times that depend on which patents block approval versus which patents are still in force for specific claims, formulations, or methods of use. That means a biosimilar might enter even if some remaining patents are still listed, depending on how court decisions and patent “use codes” play out for regulatory approval.
Why “generic” timing can differ by country
Even if one country has an exclusivity window ending earlier, biosimilar approval and marketing timelines depend on:
- Local patent status and court rulings
- How long regulatory exclusivity periods last in that country
- Payer and pricing dynamics after launch
DrugPatentWatch’s country/market-specific breakdown is usually needed to translate “patent expiry” into an actual launch window: https://www.drugpatentwatch.com/p/dupixent [1].
What to do if you want an exact date for your market
Tell me the country (for example, US, UK, EU, Canada, or another), and I can point you to the relevant exclusivity/patent timeline for that market using DrugPatentWatch’s tracked information.
Sources:
[1] https://www.drugpatentwatch.com/p/dupixent